"Fang Tuo Bio" completes $ 160 million in Series B financing

On the 19th news of Entrepreneurship, Fintera therapeutics announced the completion of $ 160 million in Series B financing, led by Boyu Capital and Sequoia China, and investment institutions such as Zhengxingu and Shibu Investment participated in the follow -up investment. Capital and Hongyuan Capital continue to bless.

According to the company's information, Fang Tuo Bio was established in 2019, bringing together professionals with rich innovative gene drug research and development, production, registration, and clinical research and management experience in China and the United States. High -quality, patient -available reorganized glands -related viruses (RAAV) carrier gene therapy products to meet the clinical treatment needs of global genetic and chronic diseases. It is reported that Fang Tuo Bio has received a total of $ 195 million in financing.

At present, Fang Tuo Bio, the first innovative product, has obtained clinical trial permits of the US Food and Drug Administration (FDA). It is understood that FT-001 is a restructuring gonad-related virus (AAV) gene therapy drug caused by genetic retinopathy caused by the RPE65 gene mutation. The disease is manifested as an early age, and the vision is gradually lost or even blind. At present, there is no validity in China. Therapeutic drugs. It took less than two years from the beginning of FT-001 to obtaining the FDA clinical trial permit, which undoubtedly showed the execution of Fangtuo Bio; at the same time, other gene therapy drugs developed by Fangtuo Company have also Start preparing for clinical research. In the future, Fang Tuo Bio will actively invest in gene therapy drug development and production to better help global patients.

Smart bud Pharmsnap Global New Drug Information Database shows that Fang Tuo Bio is mainly focused on eye diseases. At present, FT-001 has obtained clinical trials in China.

- END -